Vanda’s Fanapt Approval Is FDA U-Turn
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “not approvable” letter for the atypical antipsychotic –only 10 months ago – requested comparative trials against Risperdal and Zyprexa. But approval came without that, although labeling sets up a difficult marketing task.
You may also be interested in...
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.